

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO					
10/677,956	10/01/2003	Suzanne Zebedee	323-100US D	9260					
7:	590 09/27/2006	EXAM	INER						
Joseph E. Muc		LUCAS, ZACHARIAH							
Joseph E. Muet 8th Floor	h Law Corporation	•	ART UNIT	ART UNIT PAPER NUMBER					
225 South Lake	e Avenue	. 1648							
Pasadena, CA	91101		DATE MAILED: 09/27/2006						

Please find below and/or attached an Office communication concerning this application or proceeding.

Application/Control Number: 10/677,956 Page 2

Art Unit: 1648

Sequence Compliance

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth below or on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

The submitted CRF and paper copies of the sequence listing do not match. The CRF has 74 sequences, whereas the paper copy shows 76 sequences. See attached: Raw Sequence Listing (showing that 74 sequences are present in the listing), and pages 1 and 41 of paper copy (showing that 76 sequences are present in that copy). Because these two listings do not match, the Applicant has not complied with the sequence rules (esp., 37 CFR 1.821(e)).

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zachariah Lucas whose telephone number is 571-272-0905. The examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

Application/Control Number: 10/677,956 Page 3

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Z. Lucas

Patent Examiner

RAW SEQUENCE LISTING

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.

Application Serial Number:	10/677,9563
Source:	IFW16
Date Processed by STIC:	09/14/2006
	, , ,

ENTERED



IFW16

RAW SEQUENCE LISTING DATE: 09/14/2006
PATENT APPLICATION: US/10/677,956B TIME: 15:32:14

Input Set : E:\16988.ST25.txt

```
5 <110> APPLICANT: Zebedee, Suzanne
             Inchauspe, Genevieve
             Nasoff, Marc S.
      8
             Prince, Alfred M.
     10 <120> TITLE OF INVENTION: METHODS AND SYSTEMS FOR PRODUCING RECOMBINANT
VIRAL ANTIGENS
     12 <130> FILE REFERENCE: 323-100USD
     14 <140> CURRENT APPLICATION NUMBER: 10/677,956B
     15 <141> CURRENT FILING DATE: 2003-10-01
     17 <150> PRIOR APPLICATION NUMBER: 08/931,855
     18 <151> PRIOR FILING DATE: 1997-09-16
     20 <150> PRIOR APPLICATION NUMBER: 08/563,733
     21 <151> PRIOR FILING DATE: 1995-11-08
     23 <150> PRIOR APPLICATION NUMBER: 08/272,271
     24 <151> PRIOR FILING DATE: 1994-07-08
     26 <150> PRIOR APPLICATION NUMBER: 07/616,369
     27 <151> PRIOR FILING DATE: 1990-11-21
     29 <150> PRIOR APPLICATION NUMBER: 07/573,643
    30 <151> PRIOR FILING DATE: 1990-08-27
    32 <160> NUMBER OF SEQ ID NOS: 74
    34 <170> SOFTWARE: PatentIn version 3.3
    36 <210> SEQ ID NO: 1
    37 <211> LENGTH: 795
    38 <212> TYPE: DNA
    39 <213> ORGANISM: Human immunodeficiency virus
  42 <220> FEATURE:
    43 <221> NAME/KEY: CDS
    44 <222> LOCATION: (16)..(789)
    46 <400> SEQUENCE: 1
    47 aggagggttt ttcat atg cca atc gtg cag aac atc cag ggg caa atg gta
                                                                              51
    48 .
                        Met Pro Ile Val Gln Asn Ile Gln Gly Gln Met Val
    49
                         1
                                        5
    51 cat cag gcc ata tca cct aga act tta aat gca tgg gta aaa gta gta
                                                                              99
    52 His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val
               15
                                    20
    55 gaa gag aag gct ttc agc cca gaa gtg ata ccc atg ttt tca gca tta
                                                                             147
    56 Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu
                                35
    59 tca gaa gga gcc acc cca caa gat tta aac acc atg cta aac aca gtg
                                                                             195
    60 Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val
                            50
                                                55
    63 ggg gga cat caa gca gcc atg caa atg tta aaa gag acc atc aat gag
                                                                             243
    64 Gly Gly His Gln Ala Ala Met Gln Met Leu Lys Glu Thr Ile Asn Glu
    65
```

RAW SEQUENCE LISTING DATE: 09/14/2006
PATENT APPLICATION: US/10/677,956B TIME: 15:32:14

Input Set : E:\16988.ST25.txt

					_			•			_						
67	gaa	gct	gca	gaa	tgg	gat	aga	gtg	cat	cca	gtg	cat	gca	ggg	cct	att	291
							Arg										
69				80	_	_			85					90			
71	gca	cca	ggc	cag	atg	aga	gaa	cca	agg	gga	agt	gac	ata	gca	gga	act	339
72	Ala	Pro	Gly	Gln	Met	Arg	Glu	Pro	Arg	Gly	Ser	Asp	Ile	Āla	Gly	Thr	
73			95			_		100	_	_		_	105		-		
75	act	agt	acc	ctt	cag	gaa	caa	ata	gga	tgg	atg	aca	aat	aat	cca	cct	387
76	Thr	Ser	Thr	Leu	Gln	Glu	Gln	Ile	Gly	Trp	Met	Thr	Asn	Asn	Pro	Pro	
77		110					115		_	_		120					
79	atc	cca	gta	gga	gaa	att	tat	aaa	aga	tgg	ata	atc	ctg	gga	tta	aat	435
80	Ile	Pro	Val	Gly	Glu	Ile	Tyr	Lys	Arg	Trp	Ile	Ile	Leu	Gly	Leu	Asn	
81	125					130					135					140	
83	aaa	ata	gta	aga	atg	tat	agc	cct	acc	agc	att	ctg	gac	ata	aga	caa	483
84	Lys	Ile	Val	Arg	Met	Tyr	Ser	Pro	Thr	Ser	Ile	Leu	Asp	Ile	Arg	Gln	
85					145					150					155		
87	gga	cca	aag	gaa	CCC	ttt	aga	gac	tat	gta	gac	cgg	ttc	tat	aaa	act	531
88	Gly	Pro	Lys	Glu	Pro	Phe	Arg	Asp	Tyr	Val	Asp	Arg	Phe	Tyr	Lys	Thr	
89				160					165					170			
							tca										579
92	Leu	Arg	Ala	Glu	Gln	Ala	Ser	Gln	Glu	Val	Lys	Asn	Trp	Met	Thr	Glu	
93			175					180					185				
							gcg										627
	Thr		Leu	Val	Gln	Asn	Ala	Asn	Pro	Asp	Cys	Lys	Thr	Ile	Leu	Lys	
97		190					195					200					
							aca										675
			ı Gly	Pro	Ala			Lev	ı Glı	ı Glı			Thi	Ala	Cys	Gln	
	. 205					210					215					220	
																, tgt	723
		Val	. Gly	/ Gly			a Asr	Glr	ı Glr			ı Sei	Leu	ıTr	_	Cys	
105					225					230					235		
																ggc	771
		GIY	Lys			. Суя	з Туг	Thi			. Lys	Trp) Asr	_		Gly	
109	•	٠	·	240					245	•	•			250)		
							, taa	itaa									795
		гу			Val	. Let	1										
113		0- 0	255			•											
	<21		_														
	<21																
	<21																
	<40					idii 1	mmun	iodei	.ICIE	ncy	VIIU	ıs					
			~			7.55			. c1.		Mat	11-1	1113	. ~1-		Ile	
124		PIC	116	· val	5	. ASI	1 116	GII	GIY		i Met	. vai	птр	GII		ire	
		Pro	Δτα	The		1 Don	. Δ1≘	ጥቍ	. Val	10	1751	\ 10 = 17	G1.	. G1.	15	Ala	
128			9	20	70	. Hali	. Ala		25	בעם.	, val	. val	GIL	30	. nyb	nia	
		Ser	Pro		Val	Tle	Pro	Met		Ser	- ا م	T.e.	Ser		Gly	Ala	
132			35					40	FILE	. Jer	. Ala	ne u	45	GIU	. Сту	vrq	
		Pro	-	Asn	Len	Asn	Thr		T.e.	Деп	The	· Val		r Gla	, Hic	Gln	
136		50					55					60		U-y	***	GIII	
												~ ~					

RAW SEQUENCE LISTING
PATENT APPLICATION: US/10/677,956B

DATE: 09/14/2006
TIME: 15:32:14

Input Set : E:\16988.ST25.txt

		Ala	Met	Gln	Met	Leu	Lys	Glu	Thr	Ile	Asn	Glu	Glu	Ala	Ala	Glu	
140						70					75					80	
143 144	Trp	Asp	Arg	Val	His 85	Pro	Val	His	Ala	Gly 90	Pro	Ile	Ala	Pro	Gly 95	Gln	
147 148	Met	Arg	Glu	Pro 100	Arg	Gly	Ser	Asp	Ile 105	Ala	Gly	Thr	Thr	Ser	Thr	Leu	
	Gln	Glu	Gln		Glv	Trn	Met	Thr		Agn	Pro	Pro	Tla		Val	Gly	
152		0_0	115		017		*****	120		no		110	125	110	Val	Gly	
	Glu	Ile		Lvs	Ara	Tro	Ile		Leu	Glv	Len	Asn		Tle	Val	Ara	
156		130	-1-	-1-	5		135			V-1		140	-		,,,	9	
159	Met	Tyr	Ser	Pro	Thr	Ser		Leu	Asp	Ile	Arq		Glv	Pro	Lvs	Glu	
	145	•				150			•		155				-2-	160	
163	Pro	Phe	Arg	Asp	Tyr	Val	Asp	Arg	Phe	Tyr	Lys	Thr	Leu	Arq	Ala		
164			_	_	165		_	_		170	•			_	175		
167	Gln	Ala	Ser	Gln	Glu	Val	Lys	Asn	Trp	Met	Thr	Glu	Thr	Leu	Leu	Val	
168				180			-		185					190			
171	Gln	Asn	Ala	Asn	Pro	Asp	Суs	Lys	Thr	Ile	Leu	Lys	Ala	Leu	Gly	Pro	
172			195					200					205		_		
175	Ala	Ala	Thr	Leu	Ģlu	Glu	Met	Met	Thr	Ala	Cys	Gln	Gly	Val	Gly	Gly	
176		210					215					220					•
179	Pro	Lys	Asn	Gln	Gln	Leu	Leu	Ser	Leu	Trp	Gly	Cys	Lys	Gly	Lys	Leu	
	225					230					235					240	
	Val	Cys	Tyr	Thr	Ser	Val	Lys	Trp	Asn	Gly	Pro	Gly	His	Lys	Ala	Arg	
184					245					250					255		
	Val																
)> \$E															
		L> LE			95												
		2> TY			**												
		3> OF			Huma	an in	munc	oderi	cler	icy v	/irus	3					
)> FE L> NA			CDC												
		2> LC	•				2001										
)> SE					(09)										
						1 002	ato	ato	r cac	, 220	· atc				a+c	ggta	51
203	~99	*3334		·ccuc												. Val	31
204					1				5		• •••	. 011		10	. Met	. vai	
	cat	cag	qcc	ata	_	cct	aσa	act	tta	aat	gca	taa	qta	-	αta	gta	99
		Gln															,,,
208			15				5	20					25	-1-			
210	qaa	gag	aaq	act	ttc	agc	cca	qaa	ata	ata	ccc	ata		tca	gca	tta	147
		Glu															
212		30	•				35					40					
214	tca	gaa	gga	gcc	acc	cca	caa	gat	tta	aac	acc	atg	cta	aac	aca	qtq	195
		Glu															
216			_			50		_			55					60	
218	999	gga	cat	caa	gca	gcc	atg	caa	atg	tta	aaa	gag	acc	atc	aat	gag	243
		Gly															
220					65					70					75		
222	gaa	gct	gca	gaa	tgg	gat	aga	gtg	cat	cca	gtg	cat	gca	999	cct	att	291
														-			

RAW SEQUENCE LISTING DATE: 09/14/2006
PATENT APPLICATION: US/10/677,956B TIME: 15:32:14

Input Set : E:\16988.ST25.txt

•				000	puc .	Jec.	21. (CKF4	1031	1200	0 100	1133	OD.I	aw.			
223	Glu	Ala	Ala	Glu	Trp	Asp	Arq	Val	His	Pro	Val	His	Ala	Glv	Pro	Ile	
224				80	-	•	_		85					90			
226	gca	cca	ggc	cag	atg	aga	gaa	cca	agg	gga	agt	gac	ata	gca	gga	act	339
	Ala	Pro		Gln	Met	Arg	Glu		Arg	Gly	Ser	Asp	Ile	Ala	Gly	Thr	
228			95		•			100	•				105				
230	act	agt	acc	ctt	cag	gaa	caa	ata	gga	tgg	atg	aca	aat	aat	cca	cct	. 387
231	Thr		Thr	Leu	GIn	GIu		Ile	Gly	Trp	Met		Asn	Asn	Pro	Pro	
	2+0	110	at a	~~~	~~~	2++	115			.		120					435
235	atc Ile	Pro	Val	Glv	Glu	Tlo	Tur	Luc	Ara	Trn	Tla	Tlo	Lou	gga	tta	aac	435
	125		• • • •	013	014	130	-3-	Бåз	rrg	ııp	135	116	пеп	GIY	neu	140	
	aaa	ata	qta	aqa	atq		agc	cct	acc	agc		cta	gac	ata	aga		483
239	Lys	Ile	Val	Arg	Met	Tyr	Ser	Pro	Thr	Ser	Ile	Leu	Asp	Ile	Arq	Gln	
240					145	_				150			-		155		
242	gga	cca	aag	gaa	CCC	ttt	aga	gac	tat	gta	gac	cgg	ttc	tat	aaa	act	531
	Gly	Pro	Lys		Pro	Phe	Arg	Asp		Val	Asp	Arg	Phe	Tyr	Lys	Thr	
244				160					165					170			
246	cta	aga	gcc	gag	caa	gct	tca	cag	gag	gta	aaa	aat	tgg	atg	aca	gaa	579
247	Leu	Arg	175	GIU	GIN	Ата	ser	180	GIU	vaı	rys	Asn		Met	Thr	Glu	
	acc	tta		atc	caa	aat	aca		cca	ast	tat	220	185	a++	++-	222	627
251	Thr	Leu	Leu	Val	Gln	Asn	Ala	Asn	Pro	Asp	Cvs	Lvs	Thr	Tle	T.e.ii	Lvs	027
252		190					195				0,0	200				- 2,5	
254	gca	ttg	gga	cca	gcg	gct	aca	cta	gaa	gaa	atg		aca	gca	tgt	cag	675
255	Ala	Leu	Gly	Pro	Ala	Ala	Thr	Leu	Glu	Glu	Met	Met	Thr	Āla	Cys	Gln	
	205					210					215					220	
258	gga	gta	gga	gga	CCC	aaa	aat	caa	caa	aga	tta	aạt	tta	tgg	999	tgt	723
	Gly	Val	Gly	Gly		Lys	Asn	Gln	Gln		Leu	Asn	Leu	Trp	_	Cys	
260	222	~~~	222	a++	225					230					235		
263	aaa Lys	61v	Lve	Len	Tla	Cyc	Tur	Thr	Cor	gtt	Lvc	T ~	Aar	gga	CCC	ggc	771
264	-,-	0-7	_,,	240	-10	Cyb	- 7 -	****	245	Val	ny o	11p	H2II	250	FIO	Gry	
266	cat	aag.	gca.		gtt	ttg	taat	aa									· 795
267	His	Lys	Āla	Arg	Val	Leu											
268			255														
	<210																
_	<211				8												
	<212																
	<213 <400					ın in	munc	deri	cier	icy i	/irus	3					
	Met					Aan	Tla	Cln	GI.	C1 n	Mot	17-1	ui a	~1 <u>~</u>	21.	T1.	
279		110	116		5	VOII	116	GIII	GIY	10	Mec	val	uis	GIII	15	ire	
	Ser	Pro	Ara .	Thr	Leu	Asn	Ala	Trp	Val		Val	Val	Glu	Glu		Δla	
283				20					25					30	_,_		
286	Phe	Ser	Pro	Glu	Val	Ile	Pro	Met		Ser	Ala	Leu	Ser		Gly	Ala	
287			35					40					45				
290	Thr	Pro	Gln	Asp	Leu	Asn		Met	Leu	Asn	Thr	Val	Gly	Gly	His	Gln	
291		50		_,		_	55					60					
294	Ala	AIA	Met	GIN	Met	Leu	ŗàs	Glu	Thr	Ile	Asn	Glu	Glu	Ala	Ala	Glu	

RAW SEQUENCE LISTING DATE: 09/14/2006
PATENT APPLICATION: US/10/677,956B TIME: 15:32:14

Input Set : E:\16988.ST25.txt

	65					70					75	•				80	
	Trp	Asp	Arg	Val	His	Pro	Val	His	Ala	Gly	Pro	Ile	Ala	Pro	Gly	Gln	
299					85					90					95		
302	Met	Arg	Glu	Pro	Arg	Gly	Ser	Asp	Ile	Ala	Gly	Thr	Thr	Ser	Thr	Leu	
303				100					105					110			
306	Gln	Glu	Gln	Ile	Gly	Trp	Met	Thr	Asn	Asn	Pro	Pro	Ile	Pro	Val	Gly	
307			115					120					125				
310	Glu	Ile	Tyr	Lys	Arg	Trp	Ile	Ile	Leu	Gly	Leu	Asn	Lys	Ile	Val	Arg	
311		130					135			_		140				_	
314	Met	Tyr	Ser	Pro	Thr	Ser	Ile	Leu	Asp	Ile	Arg	Gln	Gly	Pro	Lys	Glu	
	145					150			_		155		_		-	160	
318	Pro	Phe	Arg	Asp	Tyr	Val	Asp	Arg	Phe	Tyr	Lys	Thr	Leu	Arg	Ala	Glu	
319			_	-	165		_	_		170	•			-	175		
322	Gln	Ala	Ser	Gln	Glu	Val	Lys	Asn	Trp	Met	Thr	Glu	Thr	Leu	Leu	Val	
323				180			•		185					190			
326	Gln	Asn	Ala	Asn	Pro	Asp	Cvs	Lvs		Ile	Leu	Lvs	Ala		Glv	Pro	
327			195				-1-	200				-1-	205		1		
330	Ala	Ala		Leu	Glu	Glu	Met		Thr	Ala	Cvs	Gln		Val	Glv	Glv	
331		210					215				-7-	220	U -,		,	027	
	Pro	Lys	Asn	Gln	Gln	Ara		Asn	Leu	Tro	Glv		Lvs	Glv	Lvs	T.eu	
	225					230					235	O _I O	2,5	0-7	, U	240	
		Cys	Tvr	Thr	Ser		T.vg	Trn	Agn	Glv		Glv	Нia	Tare	Δla		
339		- 7	-1-		245		2,5		*****	250	110	Cry		פעם	255	ur 9	
	Val	Len			243					250					233		
		0> SI	O TE	א מ	. 5												
			~														
	~ / 1	1 5 1.1	いんしょ	3· 70	35												
				1: 79	95												
348	<212	2> T	PE:	DNA		an in	nmı 177	ndef:	icie	acv. 1	ci mie						
348 349	<213 <213	2> TY 3> OF	(PE:	DNA SM:		an in	nmunc	odef:	icier	ncy v	virus	5					
348 349 352	<213 <213 <220	2> T) 3> OF 0> FF	(PE : RGAN] LATUI	DNA ISM: RE:	Huma	an in	nmunc	odefi	icier	icy v	virus	5					
348 349 352 353	<213 <213 <220 <223	2> TY 3> OF 0> FF 1> NA	(PE: RGAN] EATUI AME/I	DNA (SM: RE: KEY:	Huma			odefi	icier	icy v	virus	3					
348 349 352 353 354	<213 <213 <220 <223 <223	2> T) 3> OF 0> FF 1> NA 2> LO	(PE: RGAN] BATUE AME/E CAT]	DNA ISM: RE: REY: ION:	Huma CDS (16)			odef	icier	icy v	virus	5	٠				
348 349 352 353 354 356	<213 <221 <220 <223 <223 <400	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF	(PE: RGAN) EATUR ME/R CAT) EQUER	DNA ISM: RE: CEY: ION: ICE:	Huma CDS (16)	(7	789)									v at a	51
348 349 352 353 354 356 357	<213 <221 <220 <223 <223 <400	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF	(PE: RGAN) EATUR ME/R CAT) EQUER	DNA ISM: RE: CEY: ION: ICE:	Huma CDS (16) 5	(7 g cca	789) a ato	e gtç	g cag	, aac	e ato	cag				g gta	51
348 349 352 353 354 356 357 358	<213 <221 <220 <223 <223 <400	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF	(PE: RGAN) EATUR ME/R CAT) EQUER	DNA ISM: RE: CEY: ION: ICE:	Huma CDS (16) 5 ato	(7 g cca	789) a ato	e gtç	g cag	, aac	e ato	cag		/ Glr		g gta : Val	51
348 349 352 353 354 356 357 358 359	<212 <221 <220 <222 <222 <400 aggs	2> T? 3> OB 0> FB 1> NA 2> LO 0> SB agggt	(PE: RGAN) EATUR ME/R CCAT) EQUEN	DNA ISM: RE: REY: ION: ICE:	Huma CDS (16) 5 ato	(7	789) a ato o Ile	e gte val	g cag L Glr 5	g aac n Asr	ato 1 Ile	c cag	ı Glş	/ Glr 10	ı Met	: Val	
348 349 352 353 354 356 357 358 359 361	<212 <221 <222 <222 <400 agga	2> TY 3> OF 0> FF 1> NX 2> LO 0> SF agggt	(PE: RGAN) RATUE AME/I DCAT) RQUEN tt t	DNA ISM: RE: REY: ION: ICE: ICE:	Huma CDS (16) 5 ato	(? g cca e Pro	789) a ato o Ile aga	gtg Val	g cag L Glr 5 tta	g aad 1 Asr aat	ato 111e	cag Gli tgg	ı Gly gta	/ Glr 10 aaa	n Met gta	: Val gta	51 99
348 349 352 353 354 356 357 358 359 361 362	<212 <221 <222 <222 <400 agga	2> T? 3> OB 0> FB 1> NA 2> LO 0> SB agggt	PE: RGANI RATUE AME/E DCATI ROUEN EQUEN Ett t gcc Ala	DNA ISM: RE: REY: ION: ICE: ICE:	Huma CDS (16) 5 ato	(? g cca e Pro	789) a ato o Ile aga	gto Val act Thr	g cag L Glr 5 tta	g aad 1 Asr aat	ato 111e	cag Gli tgg	gta Val	/ Glr 10 aaa	n Met gta	: Val gta	
348 349 352 353 354 356 357 358 359 361 362 363	<213 <213 <220 <223 <400 agga	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln	PE: RGANI EATUR ME/I DCATI EQUEN Ett t gcc Ala 15	DNA ISM: RE: CEY: ON: ICE: tcat ata Ile	CDS (16) 5 c ato Met 1 tca Ser	cct Pro	789) a ato o Ile aga Arg	gte Val act Thr 20	g cag Glr 5 tta Leu	g aac n Asr aat Asn	e ato n Ile gca Ala	c cag e Glr tgg Trp	gta Val 25	Glr 10 aaa Lys	n Met gta Val	yal gta Val	99
348 349 352 353 354 356 357 358 361 362 363 365	<21: <22: <22: <22: <40: agga cat His	2 > TY 3 > OF 0 > FF 1 > NX 2 > LO 0 > SF agggt cag Gln	RGANI RGANI RGATUE AME/E DCATI EQUEN tt t gcc Ala 15 aag	DNA ISM: ISM: ISM: ISM: ISM: ISM: ISM: ISM:	Huma CDS (16) 5 ato Met 1 tca Ser	cct Pro	789) a ato o Ile aga Arg	e gto act Thr 20 gaa	g cag Glr 5 tta Leu gtg	g aac n Asr aat Asn ata	gca Ala	c cag glr tgg Trp atg	gta Val 25 ttt	Glr 10 aaa Lys tca	gta Val gca	yta gta Val tta	
348 349 352 353 354 356 357 358 359 361 362 363 365 366	<21: <22: <22: <22: <40: agga cat His	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu	RGANI RGANI RGATUE AME/E DCATI EQUEN tt t gcc Ala 15 aag	DNA ISM: ISM: ISM: ISM: ISM: ISM: ISM: ISM:	Huma CDS (16) 5 ato Met 1 tca Ser	cct Pro	789) a ato b Ile aga Arg cca Pro	e gto act Thr 20 gaa	g cag Glr 5 tta Leu gtg	g aac n Asr aat Asn ata	gca Ala	c cag e Glr tgg Trp atg Met	gta Val 25 ttt	Glr 10 aaa Lys tca	gta Val gca	yta gta Val tta	99
348 349 352 353 354 356 357 358 369 361 362 363 365 366 367	<212 <221 <222 <222 <400 aggs cat His	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30	PE: RGANI RATUR AME/R CATI RQUEN SEQUEN SECUEN SECU	DNA ISM: ISM: ISM: ISM: ISM: ISM: ISM: ISM:	CDS (16) 5 ato Met 1 tca Ser ttc	cct Pro agc Ser	789) a ato b Ile aga Arg cca Pro 35	act Thr 20 gaa Glu	g cag Glr 5 tta Leu gtg Val	g aac n Asr aat Asn ata Ile	c ato Ile gca Ala ccc Pro	tgg Trp atg Met	gta Val 25 ttt Phe	Glr 10 aaa Lys tca Ser	gta Val gca Ala	gta gta Val tta Leu	99 147
348 349 352 353 354 356 357 358 361 362 363 365 366 367 369	<212 <221 <222 <222 <400 aggs cat His gaa Glu tca	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa	PE: RGANI RATUR AME/R CATI R QUEN tt t gcc Ala 15 aag Lys	DNA ISM: ISM: ISM: ISM: ISM: ISM: ISM: ISM:	Huma CDS (16) 5 ato Met 1 tca Ser ttc Phe	cct Pro agc Ser	789) a ato b Ile aga Arg cca Pro 35 caa	act Thr 20 gaa Glu	g cag Glr 5 tta Leu gtg Val	g aac n Asr aat Asn ata Ile	gca Ala ccc Pro	tgg Trp atg Met 40	gta Val 25 ttt Phe	Glr 10 aaa Lys tca Ser	gta Val gca Ala aca	gta Val tta Leu gtg	99
348 349 352 353 354 356 357 358 369 361 365 365 366 367 369 370	<212 <221 <222 <222 <400 agga cat His gaa Glu tca Ser	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30	PE: RGANI RATUR AME/R CATI R QUEN tt t gcc Ala 15 aag Lys	DNA ISM: ISM: ISM: ISM: ISM: ISM: ISM: ISM:	Huma CDS (16) 5 ato Met 1 tca Ser ttc Phe	cct Pro agc Ser cca Pro	789) a ato b Ile aga Arg cca Pro 35 caa	act Thr 20 gaa Glu	g cag Glr 5 tta Leu gtg Val	g aac n Asr aat Asn ata Ile	gca Ala ccc Pro acc	tgg Trp atg Met 40	gta Val 25 ttt Phe	Glr 10 aaa Lys tca Ser	gta Val gca Ala aca	gta Val tta Leu gtg Val	99 147
348 349 352 353 354 356 357 368 369 365 366 367 369 370 371	<212 <221 <222 <222 <400 agga cat His gaa Glu tca Ser 45	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa Glu	PE: RGANI EATUE AME/E DCATI DCATI DCATI EQUEN tt t gcc Ala 15 aag Lys gga Gly	DNA ISM: ISM: ISM: ICE: ICON: ICE: ICAT Ata gct Ala gcc Ala	Huma CDS (16) 5 ato tca Ser ttc Phe acc	cct Pro agc Ser cca Pro 50	789) a ato aga aga Arg cca Pro 35 caa Gln	act Thr 20 gaa Glu gat Asp	g cas 1 Glr 5 tta Leu gtg Val tta Leu	aat Asn ata Ile aac Asn	gca Ala CCC Pro acc Thr	tgg Trp atg Met 40 atg	gta Val 25 ttt Phe cta Leu	Glr 10 aaa Lys tca Ser aac Asn	gta Val gca Ala aca Thr	gta Val tta Leu gtg Val 60	99 147 195
348 349 352 353 354 356 357 368 369 365 366 367 369 370 371 373	<212 <221 <222 <222 <400 agga cat His gaa Glu tca Ser 45 999	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa Glu gga	PE: RGANI RATUI AME/I DCATI DC	DNA ISM: ISM: ISE: ION: ICE: ICAT Ata Ile gct Ala gcc Ala caa	Huma CDS (16) 5 atc Met 1 tca Ser ttc Phe acc Thr	cct Pro agc Ser cca Pro 50	789) a atc aga arg cca Pro 35 caa Gln atg	act Thr 20 gaa Glu gat Asp	g cas I Glr 5 tta Leu gtg Val tta Leu	aat Asn ata Ile aac Asn	gca Ala CCC Pro acc Thr 55	tgg Trp atg Met 40 atg Met	gta Val 25 ttt Phe cta Leu	Glr 10 aaa Lys tca Ser aac Asn	gta Val gca Ala aca Thr	gta Val tta Leu gtg Val 60 gag	99 147
348 349 352 353 354 357 358 359 361 362 363 365 366 367 370 371 373 374	<212 <221 <222 <222 <400 agga cat His gaa Glu tca Ser 45 999	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa Glu	PE: RGANI RATUI AME/I DCATI DC	DNA ISM: ISM: ISE: ION: ICE: ICAT Ata Ile gct Ala gcc Ala caa	Huma (16) 5 ato Met 1 tca Ser ttc Phe acc Thr	cct Pro agc Ser cca Pro 50	789) a atc aga arg cca Pro 35 caa Gln atg	act Thr 20 gaa Glu gat Asp	g cas I Glr 5 tta Leu gtg Val tta Leu	aat Asn ata Ile aac Asn tta Leu	gca Ala CCC Pro acc Thr 55	tgg trp atg Met 40 atg Met	gta Val 25 ttt Phe cta Leu	Glr 10 aaa Lys tca Ser aac Asn	gta Val gca Ala aca Thr aat Asn	gta Val tta Leu gtg Val 60 gag	99 147 195
348 349 352 353 354 357 358 359 361 362 363 365 366 367 370 371 373 374	<212 <221 <222 <222 <400 aggs cat His gaa Glu tca Ser 45 ggg Gly	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa Glu gga Gly	PE: RGANI RATUI AME/I DCATI DC	DNA ISM: ISM: ISE: ION: ICE: ICAT Ata Ile gct Ala gcc Ala caa Gln	Huma (16) 5 Ato Met 1 tca Ser ttc Phe acc Thr gca Ala 65	cct Pro agc Ser cca Pro 50 gcc	aga Arg cca Pro 35 caa Gln atg	act Thr 20 gaa Glu gat Asp caa Gln	g cag Glr 5 tta Leu gtg Val tta Leu atg Met	aat Asn ata Ile aac Asn tta Leu 70	gca Ala ccc Pro acc Thr 55 aaa Lys	tgg Trp atg Met 40 atg Met gag Glu	gta Val 25 ttt Phe cta Leu acc	Glr 10 aaa Lys tca Ser aac Asn atc	gta Val gca Ala aca Thr aat Asn 75	gta Val tta Leu gtg Val 60 gag Glu	99 147 195
348 349 352 353 354 357 358 359 361 362 363 365 366 367 370 371 373 374 375 377	<212 <221 <222 <222 <400 aggs cat His gaa Glu tca Ser 45 ggg Gly	2> TY 3> OF 0> FF 1> NA 2> LO 0> SF agggt cag Gln gag Glu 30 gaa Glu gga	PE: RGANI RGATUE AME/F A	DNA ISM: ISM: ISE: ION: ICE: ICAT Ata Ile gct Ala gcc Ala caa Gln gaa	Huma CDS (16) 5 Atc 1 tca Ser ttc Phe acc Thr gca Ala 65 tgg	cct Pro age Ser cca Pro 50 gcc Ala	aga Arg cca Pro 35 caa Gln atg Met	act Thr 20 gaa Glu gat Asp caa Gln	g cag Glr 5 tta Leu gtg Val tta Leu atg Met	aat Asn ata Ile aac Asn tta Leu 70 cca	gca Ala ccc Pro acc Thr 55 aaa Lys	tgg Trp atg Met 40 atg Met gag Glu	gta Val 25 ttt Phe cta Leu acc Thr	Glr 10 aaa Lys tca Ser aac Asn atc	gta Val gca Ala aca Thr aat Asn 75 cct	gta Val tta Leu . gtg Val 60 gag Glu att	99 147 195

RAW SEQUENCE LISTING ERROR SUMMARY DATE: 09/14/2006 PATENT APPLICATION: US/10/677,956B TIME: 15:32:15

Input Set : E:\16988.ST25.txt

Output Set: N:\CRF4\09142006\J677956B.raw

Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:19,20,21,22,23,24,25,26,27,28,29,31,32,33,34,35,36,37,38,39,40,41,42,43 Seq#:44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67 Seq#:68,69,70,71,73,74 VERIFICATION SUMMARY DATE: 09/14/2006 PATENT APPLICATION: US/10/677,956B TIME: 15:32:15

Input Set : E:\16988.ST25.txt
Output Set: N:\CRF4\09142006\J677956B.raw



16988 ST25.txt

SEQUENCE LISTING

<110> Zebedee, Suzanne Inchauspe, Genevieve Nasoff, Marc S. Prince, Alfred M.	
<120> METHODS AND SYSTEMS FOR PRODUCING RECOMBINANT VIRAL ANTIGENS	
<130> 323-100USD	
<140> 10/677,956 <141> 2003-10-01	
<150> 08/931,855 <151> 1997-09-16	
<150> 08/563,733 <151> 1995-11-08	
<150> 08/272,271 <151> 1994-07-08	
<150> 07/616,369 <151> 1990-11-21	
<150> 07/573,643 <151> 1990-08-27	
<160> 76	
<170> PatentIn version 3.3	
<210> 1 <211> 795 <212> DNA <213> Human immunodeficiency virus	
<220> <221> CDS <222> (16)(789)	
<pre><400> 1 aggagggttt ttcat atg cca atc gtg cag aac atc cag ggg caa atg gta 5</pre>	1
cat cag gcc ata tca cct aga act tta aat gca tgg gta aaa gta gta His Gln Ala Ile Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Val 15 20 25	9
gaa gag aag gct ttc agc cca gaa gtg ata ccc atg ttt tca gca tta Glu Glu Lys Ala Phe Ser Pro Glu Val Ile Pro Met Phe Ser Ala Leu 30 35 40	7
tca gaa gga gcc acc cca caa gat tta aac acc atg cta aac aca gtg Ser Glu Gly Ala Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val 45 50 55 60	5
ggg gga cat caa gca gcc atg caa atg tta aaa gag acc atc aat gag 24 Page 1	3

16988 ST25.txt

<210> 76 252 <211> Artificial <220> <223> Synthetic Construct <400> 76 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro 1 5 . 10 15 Thr Arg Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu 20 25 30 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu 35 40 45 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
50 60 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn 65 70 75 80 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu 85 90 95 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser 100 110 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu 115 120 125 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn 130 140 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp 145 150 160 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu 165 170 175

Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr 180 185 190

Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala 195 200 205

Page 41